IN8bio Q4 net loss narrows, cash position more than doubles

IN8bio

12/03/2026 20:45

Overview

US biopharma firm's Q4 net loss narrowed yr/yr as cash position more than doubled

Company closed $20.1 mln tranche of private placement, extending cash runway into H1 2027

Outlook

Company expects cash runway to extend into first half of 2027

IN8bio anticipates FDA guidance on regulatory pathway by second half of 2026

Company expects multiple clinical and preclinical milestones in 2026

Result Drivers

R&D expenses were $2.6 million for the three months ended December 31, 2025, compared with $3.6 million for the comparable prior year period

As of December 31, 2025, the Company had cash of $27.1 million, compared with $11.1 million as of December 31, 2024

LOWER OPERATING EXPENSES - Reduced R&D and G&A expenses contributed to a narrower net loss yr/yr

PRIVATE PLACEMENT - Closing of $20.1 mln tranche extended cash runway and supported advancement of clinical programs

Company press release: ID:nGNXHwJq2

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$4.9 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for IN8bio Inc is $7.50, about 276.9% above its March 11 closing price of $1.99

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)